Interfacing with the healthcare system is notoriously challenging. Scheduling appointments, determining insurance coverage, traveling, waiting, testing, scanning, picking up prescriptions, etc.…the list of manual tasks goes on and on.
At InnaMed, we have reimagined a major part of this journey: we make monitoring and analyzing blood test data fast and seamless, and we’re also creating a one-stop platform through which you can access and experience digital health services.
- Min investment
- Days Left
- Security Type
A SAFE is an agreement between you—the investor—and the company in which the company promises to give you a future equity stake based on the amount you invested. It also involves some kind of a triggering event that must take place in order for you to get your future equity stake. Be careful as you may only get equity if a particular event is triggered.
- February 19, 2021
- April 30, 2022
- Valuation Cap
- Deal Structure
Price Per Share: $1.00
- 96.25% - Research and development materials and contractors 3.75% - Wefunder intermediary fee
- 40% of funds would be used towards research and development materials and contractors. 40% of funds would be used for payroll. 16.25% - Facilities, marketing and legal purposes. 3.75% - Wefunder intermediary fee
CrowdLustro Research Report
Use of Proceeds
Y Combinator-backed founder and bioengineer. Previously conducted R&D at UPenn for 4+ years combining microfluidics, optics and cloud computing to develop proteomics. Work published in PNAS and exclusively licensed to another venture-backed startup.
Anup Singh, CSO
Y Combinator-backed founder and biophysicist. Previously conducted R&D for 5+ years at UCLA and UPenn on early detection of cancers and traumatic brain injury. Invited conference speaker topics ranging from precision medicine to space health.
Tom Larson, Commercial Development Lead
Executive with 25+ years of experience in the biopharma and diagnostics industries. Most recently served as Chief Commercial Officer of Ascendis Pharma. Led launches of some of the most successful drugs including Humira and Pradaxa.
No reports have been submittedBecome a Reporter